Vycor Medical INC 10-Q quarterly reports

Vycor Medical reported a net income of $20,108 for the first quarter of 2026, though substantial doubt remains regarding its ability to continue as a going concern.

Vycor Medical reported improved revenue and reduced net losses for Q3 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Vycor Medical, Inc. reported increased revenue and reduced net loss for Q2 2025, but faces significant liquidity challenges and a 'going concern' warning.

Vycor Medical's Q1 2025 shows revenue growth of 30% year-over-year, but the company continues to face net losses and substantial doubt about its ability to continue as a going concern.

Vycor Medical saw a 27% increase in revenue compared to the same quarter last year, driven by growth in its neurosurgical device division, while facing ongoing concerns about its ability to continue as a going concern.

Vycor Medical's Q2 2024 results show a decrease in revenue compared to the same period last year, alongside ongoing concerns about the company's ability to continue as a going concern.

Vycor Medical's Q1 2024 results show a net loss and a working capital deficiency, raising concerns about the company's ability to continue as a going concern.